6533b85afe1ef96bd12b9794

RESEARCH PRODUCT

Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant.

Massimo TommasinoAnnie ArslanPhilippe BirembautMartha GrodzkiGuillaume BessonChristine ClavelIngeborg ZehbeSilvia Franceschi

subject

medicine.medical_specialtyEpidemiologyUterine Cervical NeoplasmsCervical intraepithelial neoplasiaLesionCohort StudiesRisk FactorsInternal medicineEpidemiologymedicineOdds RatioHumansRisk factorbusiness.industryPapillomavirus InfectionsHPV infectionvirus diseasesOdds ratioOncogene Proteins Viralmedicine.diseaseUterine Cervical DysplasiaRepressor ProteinsOncologyCase-Control StudiesImmunologyDisease ProgressionFemaleViral diseaseFrancemedicine.symptombusinessCohort study

description

Abstract To test the significance of human papillomavirus (HPV) type 16 and HPV16 E6 variants as risk factors for viral persistence and progression to high-grade lesion, we did a nested case-control study within a cohort study of >15,000 Caucasian French women. Three groups infected with high-risk HPV were compared: (a) women with cleared infection (controls, n = 201), (b) women with persistent infection (cases, n = 87), and (c) women who progressed into high-grade lesion (cases, n = 58). Women with persistent HPV infection and those that progressed into high-grade lesions were likelier to harbor HPV16 than other high-risk HPV types [odds ratio (OR), 2.4; 95% confidence interval (95% CI), 1.3-4.3 and OR, 4.2; 95% CI, 2.2-8.1, respectively]. Notably, especially elevated ORs of persistence (3.0; 95% CI, 1.4-6.7) and progression (6.2; 95% CI, 2.7-14.3) were found among women who harbored the HPV16 350G variant. Thus, HPV type and HPV16 variant seem to be risk factors for viral persistence and progression of infections into high-grade cervical lesions. Cancer Epidemiol Biomarkers Prev 2006:15(4);820–2

10.1158/1055-9965.epi-05-0864https://pubmed.ncbi.nlm.nih.gov/16614130